DE69930269D1 - Wasserlösslische prodrugs von gehinderten phenolen - Google Patents

Wasserlösslische prodrugs von gehinderten phenolen

Info

Publication number
DE69930269D1
DE69930269D1 DE69930269T DE69930269T DE69930269D1 DE 69930269 D1 DE69930269 D1 DE 69930269D1 DE 69930269 T DE69930269 T DE 69930269T DE 69930269 T DE69930269 T DE 69930269T DE 69930269 D1 DE69930269 D1 DE 69930269D1
Authority
DE
Germany
Prior art keywords
water
phenoles
disabled
soluble prodrugs
prodrugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69930269T
Other languages
English (en)
Other versions
DE69930269T2 (de
Inventor
J Stella
J Zygmunt
Gunda Georg
S Safadi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas
Original Assignee
University of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas filed Critical University of Kansas
Application granted granted Critical
Publication of DE69930269D1 publication Critical patent/DE69930269D1/de
Publication of DE69930269T2 publication Critical patent/DE69930269T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/091Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
DE69930269T 1998-08-07 1999-08-06 Wasserlösslische prodrugs von gehinderten phenolen Expired - Lifetime DE69930269T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/131,385 US6204257B1 (en) 1998-08-07 1998-08-07 Water soluble prodrugs of hindered alcohols
US131385 1998-08-07
PCT/US1999/017779 WO2000008033A1 (en) 1998-08-07 1999-08-06 Water soluble prodrugs of hindered alcohols or phenols

Publications (2)

Publication Number Publication Date
DE69930269D1 true DE69930269D1 (de) 2006-05-04
DE69930269T2 DE69930269T2 (de) 2006-12-07

Family

ID=22449234

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69930269T Expired - Lifetime DE69930269T2 (de) 1998-08-07 1999-08-06 Wasserlösslische prodrugs von gehinderten phenolen

Country Status (27)

Country Link
US (4) US6204257B1 (de)
EP (2) EP1683803A1 (de)
JP (1) JP4554081B2 (de)
KR (1) KR100662799B1 (de)
CN (2) CN1680402A (de)
AT (1) ATE319723T1 (de)
AU (1) AU769755B2 (de)
BR (1) BR9912853A (de)
CA (1) CA2339834C (de)
CY (1) CY1105043T1 (de)
CZ (1) CZ304020B6 (de)
DE (1) DE69930269T2 (de)
DK (1) DK1102776T3 (de)
ES (1) ES2268876T3 (de)
HK (1) HK1047939B (de)
HU (1) HU229401B1 (de)
IL (1) IL141316A (de)
MX (1) MXPA01001431A (de)
NO (1) NO330357B1 (de)
NZ (1) NZ509795A (de)
PL (1) PL198141B1 (de)
PT (1) PT1102776E (de)
RU (1) RU2235727C2 (de)
TR (1) TR200100772T2 (de)
UA (1) UA73479C2 (de)
WO (1) WO2000008033A1 (de)
ZA (1) ZA200101039B (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
AU759641B2 (en) * 1998-08-19 2003-04-17 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6362234B1 (en) * 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
IL158385A0 (en) * 2001-04-20 2004-05-12 Debiopharm Sa Modified cyclosporin which can be used as a pro-drug and use thereof
WO2003026632A2 (en) * 2001-09-26 2003-04-03 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
CN100413508C (zh) * 2001-12-21 2008-08-27 Mgigp公司 用于制备醇和酚的水溶性膦酰氧基甲基衍生物的方法
BR0215303A (pt) * 2001-12-28 2005-04-05 Guilford Pharm Inc Formulações farmacêuticas de base aquosa de pró-drogas solúveis em água de propofol
IL164217A0 (en) * 2002-04-08 2005-12-18 Guilford Pharm Inc Pharmaceutical compositions containing water-soluble propofol and methods of administering same
ITRM20020306A1 (it) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
ZA200504940B (en) * 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
WO2005023204A2 (en) * 2003-09-09 2005-03-17 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
US7250412B2 (en) * 2003-10-24 2007-07-31 Auspex Pharmaceuticals, Inc. PH sensitive prodrugs of 2,6-Diisopropylphenol
US7834043B2 (en) * 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
US20070202158A1 (en) * 2003-12-17 2007-08-30 Mgi Gp, Inc. Methods Of Administering Water-Soluble Prodrugs Of Propofol For Extended Sedation
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
PL1745064T3 (pl) 2004-04-15 2011-06-30 Onyx Therapeutics Inc Związki do hamowania enzymu proteazomu
US20050256324A1 (en) * 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
CN101014612B (zh) 2004-05-10 2014-11-26 欧尼斯治疗公司 用于酶抑制的化合物
NZ590128A (en) * 2004-07-06 2012-08-31 Abbott Lab Prodrugs of HIV protease inhibitors
ATE410408T1 (de) * 2004-07-12 2008-10-15 Xenoport Inc Von aminosäuren abgeleitete prodrugs von propofolzusammensetzungen und anwendungen davon
WO2006017351A1 (en) * 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
AU2005281359A1 (en) * 2004-08-26 2006-03-16 Apparao Satyam Prodrugs and codrugs containing novel bio-cleavable disulfide linkers
WO2006033911A2 (en) * 2004-09-17 2006-03-30 Mgi Gp, Inc. Methods of administering water-soluble prodrugs of propofol
EP1844000B1 (de) * 2004-12-23 2010-01-27 Xenoport, Inc. Von serinaminosäure abgeleitete prodrugs von propofol, zusammensetzungen, anwendungen und kristalline formen davon
NZ565049A (en) 2005-06-17 2012-02-24 Vital Health Sciences Pty Ltd A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
AU2006268326A1 (en) * 2005-07-12 2007-01-18 Eisai Inc. Methods of dosing propofol prodrugs for inducing mild to moderate levels of sedation
ES2396794T3 (es) 2005-08-18 2013-02-27 Zimmer Gmbh Artículos de polietileno de peso molecular ultra-alto y métodos para formar artículos de polietileno de peso molecular ultra-alto
US20080234229A1 (en) * 2005-08-18 2008-09-25 Auspex Pharmaceuticals, Inc. Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders
US7589239B2 (en) * 2005-09-02 2009-09-15 Auspex Pharmaceuticals Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
US20090114877A1 (en) * 2005-09-13 2009-05-07 Eisai R&D Management Co., Ltd. Composition Containing Stability-Improved Chloromethyl Phosphate Derivatve and Process for Producing Same
US8716322B2 (en) 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
NZ573759A (en) * 2006-06-19 2012-03-30 Proteolix Inc Peptide epoxyketones for proteasome inhibition
EP2068630A4 (de) * 2006-10-05 2010-12-29 Eisai Inc Wasserbasierte pharmazeutische formulierungen aus wasserlöslichen prodrugs von propofol
US20080161400A1 (en) * 2006-10-26 2008-07-03 Xenoport, Inc. Use of forms of propofol for treating diseases associated with oxidative stress
US8664290B2 (en) 2007-04-10 2014-03-04 Zimmer, Inc. Antioxidant stabilized crosslinked ultra-high molecular weight polyethylene for medical device applications
EP2564882B1 (de) 2007-04-10 2021-05-19 Zimmer, Inc. Antioxidans-stabilisiertes, vernetztes Polyethylen mit ultrahohem Molekulargewicht für Medizingeräteanwendungen
KR20100017435A (ko) 2007-05-09 2010-02-16 파마코포어, 인크. 치료 화합물
EP2292577A1 (de) 2007-05-09 2011-03-09 Pharmacofore, Inc. (+)-Stereoisomer von 2,6-di-sec-Butylphenol und Analoga davon
US20090005444A1 (en) * 2007-06-21 2009-01-01 Xenoport, Inc. Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus
FI20070574A0 (fi) * 2007-07-30 2007-07-30 Kuopion Yliopisto Vesiliukoinen propofolin etylideenifosfaatti-aihiolääke
US8427384B2 (en) 2007-09-13 2013-04-23 Aerosat Corporation Communication system with broadband antenna
JP5453269B2 (ja) * 2007-09-13 2014-03-26 エアロサット コーポレイション アンテナアレイ
US20090076141A1 (en) * 2007-09-14 2009-03-19 Xenoport, Inc. Use of Propofol Prodrugs for Treating Neuropathic Pain
US20090075947A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched fospropofol
MY166950A (en) 2007-10-04 2018-07-25 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US20090098209A1 (en) * 2007-10-15 2009-04-16 University Of Kansas Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration
WO2009120162A1 (ru) * 2008-03-25 2009-10-01 Zhukovskij Oleg Igorevich Субстанция "ua' orion"
JP5757864B2 (ja) * 2008-05-20 2015-08-05 ニューロジェシックス, インコーポレイテッド 水溶性アセトアミノフェン類似体
AU2009249069A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Carbonate prodrugs and methods of using the same
WO2010047737A2 (en) 2008-09-02 2010-04-29 Micurx Pharmaceuticals, Inc. Antimicrobial indoline compounds for treatment of bacterial infections
EP2349313A4 (de) 2008-10-21 2012-08-29 Onyx Therapeutics Inc Kombinationstherapie mit peptidepoxyketonen
CN101798302B (zh) 2009-02-06 2014-11-05 上海盟科药业有限公司 抗生素类药物1-(邻-氟苯基)二氢吡啶酮的合成及生产的方法和工艺
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
CN101845057B (zh) * 2009-03-27 2013-10-23 四川大学 取代苯酚的甲缩醛磷酸盐麻醉镇静药用化合物及制备方法
GB0905834D0 (en) 2009-04-03 2009-05-20 Seps Pharma Nv Phosphonyl-containing phenolic derivatives useful as medicaments
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
MY160392A (en) * 2009-05-07 2017-03-15 Univ Minnesota Triptolide prodrugs
CN101648973B (zh) * 2009-09-03 2012-05-30 漆又毛 水溶性紫杉烷及制备方法
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. 転移抑制のためのペプチドエポキシケトンの使用
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CN102153607B (zh) * 2010-02-11 2015-07-15 湖南方盛华美医药科技有限公司 水溶性喜树碱衍生物及包含其的药物组合物
CN102892417A (zh) 2010-03-01 2013-01-23 欧尼斯治疗公司 用于免疫蛋白酶体抑制的化合物
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
CA2795559A1 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US8399535B2 (en) * 2010-06-10 2013-03-19 Zimmer, Inc. Polymer [[s]] compositions including an antioxidant
US20120065170A1 (en) 2010-09-10 2012-03-15 Micurx Pharmaceuticals, Inc. Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections
WO2012075396A2 (en) * 2010-12-02 2012-06-07 The University Of Kansas Prodrugs of 6-cyclohexyl-1-hydroxy-4- methylpyridin-2(1h)-one and derivatives thereof
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
ITMI20110580A1 (it) * 2011-04-08 2012-10-09 Chemelectiva S R L Iintermedi utili per la preparazione di fospropofol e processo per la loro preparazione
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
WO2013044064A1 (en) 2011-09-22 2013-03-28 Neurogesx, Inc. Acetaminophen conjugates, compositions and methods of use thereof
CN102516258B (zh) * 2011-11-11 2014-06-25 正大天晴药业集团股份有限公司 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用
CN102382133B (zh) * 2011-12-02 2016-03-23 陕西合成药业股份有限公司 一种磷丙泊酚钠的制备及纯化方法
TW201414751A (zh) 2012-07-09 2014-04-16 歐尼克斯治療公司 肽環氧酮蛋白酶抑制劑之前驅藥物
US9580459B2 (en) * 2013-04-26 2017-02-28 Metselex, Inc. Water-soluble ursodeoxycholic acid prodrugs
WO2015050851A1 (en) 2013-10-01 2015-04-09 Zimmer, Inc. Polymer compositions comprising one or more protected antioxidants
US10981951B2 (en) * 2014-01-31 2021-04-20 Mayo Foundation For Medical Education And Research Therapeutics for the treatment of glaucoma
KR102428252B1 (ko) 2014-02-21 2022-08-02 상하이 미큐알엑스 파마슈티컬 컴퍼니 리미티드 치료적 투여용 수용성 o-카보닐 포스포르아미데이트 전구약물
EP3116941A1 (de) 2014-03-12 2017-01-18 Zimmer, Inc. Schmelzstabilisiertes polyethylen mit ultrahohem molekulargewicht und verfahren zu seiner herstellung
MX2017005236A (es) 2014-10-21 2017-07-26 Abbvie Inc Profarmacos de carbidopa y l-dopa y metodos de uso.
WO2016090084A1 (en) 2014-12-03 2016-06-09 Zimmer, Inc. Antioxidant-infused ultra high molecular weight polyethylene
CN106674270A (zh) * 2015-11-11 2017-05-17 陕西合成药业股份有限公司 一种磷丙泊酚钠无水合物及晶型及其制备方法和用途
CN106674269A (zh) * 2015-11-11 2017-05-17 陕西合成药业股份有限公司 一种磷丙泊酚钠四水合物及晶型及其制备方法和用途
CN106674268A (zh) * 2015-11-11 2017-05-17 陕西合成药业股份有限公司 一种磷丙泊酚钠三水合物及晶型及其制备方法和用途
WO2017096427A1 (en) 2015-12-09 2017-06-15 Phosphagenics Limited Pharmaceutical formulation
US10851123B2 (en) * 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
WO2017184871A1 (en) * 2016-04-20 2017-10-26 Abbvie Inc. Carbidopa and l-dopa prodrugs and methods of use
US11331271B2 (en) * 2016-05-27 2022-05-17 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
US11929552B2 (en) 2016-07-21 2024-03-12 Astronics Aerosat Corporation Multi-channel communications antenna
EP3558903A4 (de) 2016-12-21 2019-11-27 Avecho Biotechnology Limited Verfahren
US10992052B2 (en) 2017-08-28 2021-04-27 Astronics Aerosat Corporation Dielectric lens for antenna system
US10174138B1 (en) * 2018-01-25 2019-01-08 University Of Massachusetts Method for forming highly reactive olefin functional polymers
CN109456360B (zh) * 2018-12-17 2021-05-14 河南中医药大学 一种磷丙泊酚钠的制备方法
CN113286796A (zh) * 2019-01-30 2021-08-20 四川科伦博泰生物医药股份有限公司 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
WO2021228150A1 (zh) * 2020-05-13 2021-11-18 成都百裕制药股份有限公司 大麻素衍生物及其制备方法和在医药上的应用
CN117279664A (zh) 2021-04-10 2023-12-22 普方生物制药美国公司 Folr1结合剂、其偶联物及其使用方法
EP4326768A1 (de) 2021-04-23 2024-02-28 Profoundbio Us Co. Anti-cd70-antikörper, konjugate davon und verfahren zur verwendung davon
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2829151A (en) 1952-11-03 1958-04-01 Dow Chemical Co Chlorotoloxy-ethyl phosphates
US3271314A (en) 1958-12-04 1966-09-06 Ethyl Corp 2, 6-diisopropylphenol
GB1146173A (en) 1966-06-18 1969-03-19 Geigy Uk Ltd Production of triaryl phosphates
US3723578A (en) 1970-10-13 1973-03-27 Gaf Corp Phosphate esters of ethers of thiol substituted phenols
US4171272A (en) 1977-12-02 1979-10-16 Fmc Corporation Turbine lubricant
FR2601259B1 (fr) 1986-07-11 1990-06-22 Rhone Poulenc Chimie Nouvelles compositions tensio-actives a base d'esters phosphoriques leur procede de preparation et leur application a la formulation de matieres actives.
US5364858A (en) 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5106742A (en) 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5244903A (en) 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5053512A (en) 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5122526A (en) 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US4894456A (en) 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5122606A (en) 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US5049668A (en) 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US5180722A (en) 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
MY103951A (en) 1988-01-12 1993-10-30 Kao Corp Detergent composition
CA2014539C (en) 1989-04-17 2000-07-25 Shinichiro Umeda Water borne metallic coating composition
US5091211A (en) 1989-08-17 1992-02-25 Lord Corporation Coating method utilizing phosphoric acid esters
JPH03209414A (ja) 1990-01-12 1991-09-12 Nikon Corp 焦点調節装置
EP0553074B1 (de) 1990-10-17 1996-06-05 Tomen Corporation Verfahren und zusammensetzung zur erhöhung der aufnahme und des transportes bioaktiver wirkstoffe in pflanzen
NO310238B1 (no) 1992-12-24 2001-06-11 Bristol Myers Squibb Co Kjemiske forbindelser og farmasöytisk preparat samt anvendelse av slike preparater
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
CA2129288C (en) 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
US5731355A (en) * 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5646159A (en) 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
IT1270093B (it) 1994-09-28 1997-04-28 Zambon Spa Processo per la purificazione di 2,6-diisopropilfenolo
TW354293B (en) 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5804682A (en) 1995-11-29 1998-09-08 Henkel Corporation Aqueous dispersions of polyamides
US5637625A (en) 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
US5746973A (en) 1996-07-10 1998-05-05 Naraghi; Ali Method for reducing odorant depletion
US5939405A (en) * 1998-01-29 1999-08-17 Bristol-Myers Squibb Company Phosphate derivatives of diaryl 1,3,4-oxadiazolone
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols

Also Published As

Publication number Publication date
IL141316A (en) 2004-06-20
AU5339499A (en) 2000-02-28
KR100662799B1 (ko) 2007-01-02
CA2339834C (en) 2011-01-25
JP4554081B2 (ja) 2010-09-29
MXPA01001431A (es) 2002-11-29
PL198141B1 (pl) 2008-05-30
PL347211A1 (en) 2002-03-25
DK1102776T3 (da) 2006-07-10
IL141316A0 (en) 2002-03-10
HU229401B1 (en) 2013-12-30
NO20010659L (no) 2001-04-06
CZ2001479A3 (cs) 2001-09-12
DE69930269T2 (de) 2006-12-07
HK1047939A1 (en) 2003-03-14
US7244718B2 (en) 2007-07-17
CY1105043T1 (el) 2010-03-03
CN1198834C (zh) 2005-04-27
US20050090431A1 (en) 2005-04-28
CN1680402A (zh) 2005-10-12
US6872838B2 (en) 2005-03-29
CN1357000A (zh) 2002-07-03
HUP0200317A2 (en) 2002-06-29
EP1102776A1 (de) 2001-05-30
US6204257B1 (en) 2001-03-20
WO2000008033A1 (en) 2000-02-17
NO20010659D0 (no) 2001-02-07
NO330357B1 (no) 2011-04-04
JP2002522443A (ja) 2002-07-23
ES2268876T3 (es) 2007-03-16
HK1047939B (zh) 2005-11-18
RU2235727C2 (ru) 2004-09-10
PT1102776E (pt) 2007-02-28
BR9912853A (pt) 2001-10-30
ATE319723T1 (de) 2006-03-15
NZ509795A (en) 2003-10-31
CZ304020B6 (cs) 2013-08-28
CA2339834A1 (en) 2000-02-17
KR20010079627A (ko) 2001-08-22
EP1683803A1 (de) 2006-07-26
ZA200101039B (en) 2002-02-05
EP1102776B1 (de) 2006-03-08
US20010025035A1 (en) 2001-09-27
TR200100772T2 (tr) 2001-12-21
HUP0200317A3 (en) 2004-07-28
AU769755B2 (en) 2004-02-05
US20030176324A1 (en) 2003-09-18
US6451776B2 (en) 2002-09-17
UA73479C2 (uk) 2005-08-15

Similar Documents

Publication Publication Date Title
DE69930269D1 (de) Wasserlösslische prodrugs von gehinderten phenolen
IL99952A0 (en) Retroviral protease inhibiting compounds
ES2195970T3 (es) L-ribavirina y usos de la misma.
IL143747A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
FI931708A0 (fi) Herbicida substituerade aryl-haloalkylpyrazoler
ATE199906T1 (de) Phosphonat-nukleotid ester-derivate
FI903331A0 (fi) Substituerade kinazolinoner, vilka aer anvaendbara som angiotensin-ii-antagonister.
DK1200418T3 (da) Nematodicide trifluorbutener
BR9502522A (pt) Composiçao concentrada em suspensao
DE69017969D1 (de) 2-Cyclohexylpropionsäure oder Derivate davon enthaltende Riechstoffzusammensetzung.
SE9604582D0 (sv) Novel compounds
ES2154692T3 (es) Dihidrofarnesal.
IT8919735A0 (it) Procedimento per la riduzione del cod da reflui industriali o urbani.
ES2003063A4 (es) Derivados de pirrolidin-2-ona, que tengan actividad nootropica.
FI923751A0 (fi) Hexahydrobenso/f/kinolinoner.
FR2661809B3 (fr) Diffuseur personnel de parfum ou de desodorisant.
ATE238791T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum
ES2089281T3 (es) Nuevos derivados de 2-mercaptometileno-tetrahidronaftaleno y 2-carboxamida indanos como inhibidores de la encefalinasa.
PT100026A (pt) Poliamina-fenois com accao radioprotectora
DE69109953T2 (de) Alfa-fluorocarbonsäurederivate als Zwischenprodukte zur Herstellung von Fungiziden.
DK0673913T3 (da) Calcium-alkalimetalcitratforbindelser samt deres anvendelse som lægemidler
ES2117992T3 (es) Derivados de pirazina.
IT222972Z2 (it) Impianto perfezionato per il trattamento di aria inquinata o simili.
UA10153A (uk) beta-[beta'-(2,4-ДІ-ТРЕТ-АМІЛФЕНОКСИ)-ЕТОКСИ] ЕТИЛХЛОРИД ЯК НАПІВПРОДУКТ ДЛЯ ОДЕРЖАННЯ РЕЧОВИН, ЯКІ МАЮТЬ АНТИМІКРОБНІ ВЛАСТИВОСТІ

Legal Events

Date Code Title Description
8364 No opposition during term of opposition